2000 Legislation
Print Friendly

HOUSE BILL NO. 409 – Carisoprodol, controlled substance

HOUSE BILL NO. 409

View Daily Data Tracking History

View Bill Text

View Statement of Purpose / Fiscal Impact



Text to be added within a bill has been marked with Bold and
Underline. Text to be removed has been marked with
Strikethrough and Italic. How these codes are actually displayed will
vary based on the browser software you are using.

This sentence is marked with bold and underline to show added text.

This sentence is marked with strikethrough and italic, indicating
text to be removed.

Daily Data Tracking History



H0409........................................................by MR. SPEAKER
                     Requested by:  Board of Pharmacy
CONTROLLED SUBSTANCES - Amends existing law to add the drug carisoprodol to
schedule IV controlled substances.
                                                                        
01/17    House intro - 1st rdg - to printing
    Rpt prt - to Health/Wel

Bill Text


 H0409
                                                                        
  ||||              LEGISLATURE OF THE STATE OF IDAHO             ||||
 Fifty-fifth Legislature                  Second Regular Session - 2000
                                                                        
                                                                        
                              IN THE HOUSE OF REPRESENTATIVES
                                                                        
                                     HOUSE BILL NO. 409
                                                                        
                                       BY MR. SPEAKER
                              Requested by: Board of Pharmacy
                                                                        
  1                                        AN ACT
  2    RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2711,  IDAHO  CODE,  TO
  3        ADD  THE  DRUG CARISOPRODOL TO SCHEDULE IV CONTROLLED SUBSTANCES; AND PRO-
  4        VIDING AN EFFECTIVE DATE.
                                                                        
  5    Be It Enacted by the Legislature of the State of Idaho:
                                                                        
  6        SECTION 1.  That Section 37-2711, Idaho Code, be, and the same  is  hereby
  7    amended to read as follows:
                                                                        
  8        37-2711.  SCHEDULE  IV.  (a)  Schedule  IV  shall consist of the drugs and
  9    other substances, by whatever official name, common or  usual  name,  chemical
 10    name, or brand name designated, listed in this section.
 11        (b)  Narcotic  drugs.  Unless  specifically  excepted  or unless listed in
 12    another schedule, any material, compound, mixture, or  preparation  containing
 13    any  of  the  following  narcotic drugs, or their salts calculated as the free
 14    anhydrous base or alkaloid, in limited quantities as set forth below:
 15        (1)  No more than 1 milligram of difenoxin and not less than 25 micrograms
 16        of atropine sulfate per dosage unit;
 17        (2)  Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,
 18        2-diphenyl-3-methyl-2-propionoxybutane).
 19        (c)  Depressants. Unless specifically excepted or unless listed in another
 20    schedule, any material, compound, mixture, or preparation which  contains  any
 21    quantity  of the following substances, including its salts, isomers, and salts
 22    of isomers whenever the existence of such salts, isomers, and salts of isomers
 23    is possible within the specific chemical designation:
 24        (1)  Alprazolam;
 25        (2)  Barbital;
 26        (3)  Bromazepam;
 27        (4)  Camazepam;
 28        (5)  Chloral betaine;
 29        (6)  Chloral hydrate;
 30        (7)  Chlordiazepoxide;
 31        (8)  Clobazam;
 32        (9)  Clonazepam;
 33        (10) Clorazepate;
 34        (11) Clotiazepam;
 35        (12) Cloxazolam;
 36        (13) Delorazepam;
 37        (14) Diazepam;
 38        (15) Estazolam;
 39        (16) Ethchlorvynol;
 40        (17) Ethinamate;
 41        (18) Ethyl loflazepate;
 42        (19) Fludiazepam;
 43        (20) Flurazepam;
                                                                        
                                           2
                                                                        
  1        (21) Halazepam;
  2        (22) Haloxazolam;
  3        (23) Ketazolam;
  4        (24) Loprazolam;
  5        (25) Lorazepam;
  6        (26) Lormetazepam;
  7        (27) Mebutamate;
  8        (28) Medazepam;
  9        (29) Meprobamate;
 10        (30) Methohexital;
 11        (31) Methylphenobarbital (mephobarbital);
 12        (32) Midazolam;
 13        (33) Nimetazepam;
 14        (34) Nitrazepam;
 15        (35) Nordiazepam;
 16        (36) Oxazepam;
 17        (37) Oxazolam;
 18        (38) Paraldehyde;
 19        (39) Petrichloral;
 20        (40) Phenobarbital;
 21        (41) Pinazepam;
 22        (42) Prazepam;
 23        (43) Temazepam;
 24        (44) Tetrazepam;
 25        (45) Triazolam;
 26        (46) Quazepam;
 27        (47) Zolpidem.
 28        (d)  Fenfluramine - Any material, compound, mixture, or preparation  which
 29    contains  any  quantity  of  the  following  substances,  including its salts,
 30    isomers (whether optical, position, or geometric), and salts of such  isomers,
 31    whenever  the existence of such salts, isomers, and salts of isomers is possi-
 32    ble:
 33        (1)  Fenfluramine.
 34        (e)  Stimulants. Unless specifically excepted or unless listed in  another
 35    schedule,  any  material, compound, mixture, or preparation which contains any
 36    quantity of the following substances having a stimulant effect on the  central
 37    nervous  system,  including  its salts, isomers (whether optical, position, or
 38    geometric), and salts of such isomers whenever the existence  of  such  salts,
 39    isomers,  and salts of isomers is possible within the specific chemical desig-
 40    nation:
 41        (1)  Cathine ((+)-norpseudoephedrine);
 42        (2)  Diethylpropion;
 43        (3)  Fencamfamin;
 44        (4)  Fenproporex;
 45        (5)  Mazindol;
 46        (6)  Mefenorex;
 47        (7)  Pemoline (including organometallic complexes and chelates thereof);
 48        (8)  Phentermine;
 49        (9)  Pipradrol;
 50        (10) Sibutramine;
 51        (11) SPA ((-)-1-dimethylamino-1,2-diphenylethane).
 52        (f)  Other substances. Unless specifically excepted, or unless  listed  in
 53    another  schedule,  any  material, compound, mixture or preparation which con-
 54    tains any quantity of the following substance, including its salts:
 55        (1)  Pentazocine;
                                                                        
                                           3
                                                                        
  1        (2)  Carisoprodol.
  2        (g)  The board may except by rule any compound,  mixture,  or  preparation
  3    containing  any  depressant substance listed in subsection (c) of this section
  4    from the application of all or any part of this act if the compound,  mixture,
  5    or  preparation contains one (1) or more active medicinal ingredients not hav-
  6    ing a depressant effect on the central nervous system, and if  the  admixtures
  7    are  included  therein in combinations, quantity, proportion, or concentration
  8    that vitiate the potential for abuse of the substances which have a depressant
  9    effect on the central nervous system.
                                                                        
 10        SECTION 2.  This act shall be in full force and effect on and  after  July
 11    1, 2000.

Statement of Purpose / Fiscal Impact


                       STATEMENT OF PURPOSE
                            RS09322

The purpose of this proposed legislation is to add the drug
carisoprodol to Schedule IV, restricting prescriptions for this
drug to five refills or six months, and placing it in the tracking
system.  This change is in response to the escalating abuse of this
drug.














                         FISCAL IMPACT
                                
There will be no impact on the General Fund, no cost to the general
public or practitioners, and implementation of legislation will be
from the Board of Pharmacy dedicated funds.










CONTACT:  Richard K. "Mick" Markuson, Director
          Idaho State Board of Pharmacy
          334-2356